Lexington, Mass., February 10, 2010 – GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that its EndoBarrier™ Gastrointestinal Liner and EndoBarrier Flow Restrictor will be highlighted by Alex Escalona, M.D., Department of Digestive Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile at the Cleveland Clinic Florida’s Ninth Annual Surgery of the Foregut Symposium and Endoscopic Natural Orifice Surgery (NOTES) Day taking place February 14-17, 2010 at the Biltmore Hotel in Coral Gables, Florida.
“I look forward to presenting clinical study information for the EndoBarrier, a compelling, emerging endoscopic technology, to my colleagues in the endoscopy and bariatric surgery fields during NOTES Day at the Surgery of the Foregut Symposium,” commented Dr. Escalona. “This symposium provides an excellent opportunity to share my own clinical experience with the EndoBarrier, as well as additional safety and efficacy data from clinical trials conducted to date, as a promising non-surgical treatment option for patients suffering from type 2 diabetes and obesity.”
Dr. Escalona will highlight EndoBarrier weight loss data in a presentation, entitled “Endoscopic duodenal-jejunal bypass: principles and results in obesity,” at 11:10 a.m. EST and additional EndoBarrier type 2 diabetes data in a presentation, entitled “Endoscopic duodenal-jejunal bypass: results in type 2 diabetes,” at 11:30 a.m. EST on Sunday, February 14, 2010.
“The incidence of type 2 diabetes and obesity continue to rise at alarming rates across the globe and innovative solutions are clearly needed,” stated Stuart A. Randle, chief executive officer of GI Dynamics. “With experience in more than 280 patients to-date, a growing body of clinical evidence demonstrates that the EndoBarrier provides a novel, non-surgical approach to treating these diseases – simultaneously improving diabetic factors in patients with type 2 diabetes and facilitating significant weight loss in obese patients. We appreciate the continued support of Dr. Escalona, and the rest of our clinical investigators and their patients, as we continue our development effort and prepare to bring the EndoBarrier to market.”
Addressing Unmet Need for Treating Type 2 Diabetes and Obesity
The EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity, received European CE mark approval for the treatment of type 2 diabetes and obesity in December 2009. Clinical trials to date involving more than 280 patients have demonstrated the significant weight loss and diabetes improvement achieved with the EndoBarrier Gastrointestinal Liner.
Type 2 diabetes affects an estimated 21 million Americans and 200 million people worldwide. According to the World Health Organization, type 2 diabetes comprises 90% of people with diabetes around the world, and is largely the result of excess body weight. Type 2 diabetes can lead to significant health problems including cardiovascular disease, retinopathy, neuropathy and nephropathy.
GI Dynamics is defining a new class of metabolic treatment options that fit between pharmaceutical regimens and surgery, called non-surgical therapeutics. Non-surgical therapeutics are designed to eliminate or reduce the risks and side effects associated with pharmaceutical regimens as well as surgical options. This new class of treatment can be performed easily and quickly without any incisions, thus reducing patient anxiety and recuperative time. Unlike traditional pharmaceutical approaches, non-surgical therapeutics remove the burden of dose regimen compliance from the patient. Additionally, non-surgical therapeutics hold the potential to improve the patient’s overall health, by providing the control necessary to institute lifestyle and nutritional improvements to maintain therapeutic effect, while being easily removed once the desired effect has been attained and lifestyle changes implemented.
About the EndoBarrier™ Gastrointestinal Liner
The patented EndoBarrier Gastrointestinal Liner is an advanced investigational, non-surgical medical device based on the EndoBarrier Technology platform for treating type 2 diabetes and obesity. The EndoBarrier Gastrointestinal Liner is placed in the GI tract endoscopically (via the mouth) to create a barrier between food and the wall of the intestine. Physicians believe that preventing food from coming into contact with the intestinal wall may alter the activation of hormonal signals that originate in the intestine, thus mimicking the effects of a Roux-en-Y gastric bypass procedure without surgery. A growing body of pre-clinical and clinical evidence supports the potential for EndoBarrier Gastrointestinal Liner to change the treatment landscape for people living with type 2 diabetes, obese people at risk for type 2 diabetes, and people with severe weight problems.
About GI Dynamics
GI Dynamics is focused on developing effective, non-surgical approaches for treating type 2 diabetes and obesity. The company’s patented EndoBarrier™ Technology has the potential to deliver medical interventions for people combating weight problems and diabetes or diabetes risk factors. Data from clinical trials demonstrate that the EndoBarrier™ Gastrointestinal Liner, an advanced device in the EndoBarrier portfolio, may provide rapid improvement in glycemic control and significant weight loss by modifying metabolic pathways.
The company is also developing the EndoBarrier Flow Restrictor, which is designed to further enhance the effectiveness of the liner by doubling the amount of weight-loss that can be achieved using the liner alone. Each device in the EndoBarrier portfolio is designed to assist patients gain control of their blood sugar and achieve a healthier body mass index (BMI). GI Dynamics is collaborating with experts in endocrinology, gastroenterology, bariatric surgery and medical weight loss on these efforts.
Based in Lexington, Massachusetts and founded in 2003, GI Dynamics is backed by top-tier investors including Advanced Technology Ventures, Catalyst Health Ventures, Cutlass Capital, Domain Associates, Johnson & Johnson Development Corporation, and Polaris Venture Partners. For more information, visit GI Dynamics online at www.gidynamics.com.